SIGN UP LOGIN    
APITBIO
Country Korea, South
Tel +82-2-6952-6346
URL apitbio.com

EXHIBITION    KOREA PHARM & BIO 2023

Booth No. 5A907
last updated on ( 2023-04-20 )

APITBIO is a specialized research and development company for antibody-based innovative drugs, with its main businesses being antibody-based innovative drug development and antibody discovery services. To support the development of antibody-based drugs, APITBIO has established a property-specialized fully human antibody library and provides customized antibody discovery services using a fully human antibody Synthetic Fab library with a diversity of 77.4 billion. This allows for efficient and rapid discovery of druggable human antibody clones with high antigen-binding ability, selectivity, low immunogenicity, high production rate, and excellent properties. The company's "Antibody-Based Innovative Drug Development Platform" consists of technologies for antibody discovery, production, optimization, and the creation of four types of bispecific antibodies, enabling the company to perform everything from target selection to non-human primate pre-toxicity testing internally.

more

EXHIBIT

Antibody discovery service using antibody-based new drug development platform

Our antibody library is a 'property-specific Fully Human Synthetic Fab Library', enabling the discovery of excellent antibodies with stability and properties (productivity/binding/aggregation) based on the highest global diversity (77.4 billion). Efficient discovery of druggable human antibody clones with high antigen binding capacity and selectivity, low immunogenicity, high yield, high productivity, and excellent physical properties in a short time.

More

COMPANY INTRODUCTION

APITBIO is a specialized research and development company for antibody-based innovative drugs, with its main businesses being antibody-based innovative drug development and antibody discovery services. To support the development of antibody-based drugs, APITBIO has established a property-specialized fully human antibody library and provides customized antibody discovery services using a fully human antibody Synthetic Fab library with a diversity of 77.4 billion. This allows for efficient and rapid discovery of druggable human antibody clones with high antigen-binding ability, selectivity, low immunogenicity, high production rate, and excellent properties. The company's "Antibody-Based Innovative Drug Development Platform" consists of technologies for antibody discovery, production, optimization, and the creation of four types of bispecific antibodies, enabling the company to perform everything from target selection to non-human primate pre-toxicity testing internally.

QUICK LINK

Inquiry

Sender
/
Purpose *
Available Amount for a deal *
Details

SHARE

SHARE

REQUEST THE VIDEO MEETING

  • (KST, UTC+09:00)

    This above time is Korean local time.
    The time for meeting is based on Korean local time.
    Please check Korean time, and choose the time available.
Sender
/ BO SUNG ENG
Receiver
박진수 / APITBIO
Purpose *
Available Amount for a deal *
Date *
Time *
Attendee 1 *
Attendee 2
Massage